Compare Adaptive Biotechnologies Corp (ADPT) vs iShares iBoxx $ High Yield Corporate Bond ETF (HYG) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs iShares iBoxx $ High Yield Corporate Bond ETF — how do they compare? Adaptive Biotechnologies Corp trades at $20.19 (market cap $3.33B), while iShares iBoxx $ High Yield Corporate Bond ETF trades at $79.67. The key difference: Adaptive Biotechnologies Corp is trading nearer its 52-week high, iShares iBoxx $ High Yield Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| ADPT | HYG | |
|---|---|---|
Market Cap | $3.33B | — |
Sector | Health | Fixed Income |
52-Week High | $22.37 | $81.32 |
52-Week Low | $10.24 | $78.72 |
Enterprise Value | $3.19B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
HYG trades at $79.87, up 0.2% today, with a neutral technical signal. The ETF shows consistent dividend distributions, including $0.42 in May 2026. Bond ETF inflows are surging 60% year-over-year as investors seek yield amid market volatility and Fed uncertainty, according to CNBC on June 25, 2026. Technical indicators show mixed signals with bearish moving averages but neutral oscillators.
Outlook remains cautious due to interest rate sensitivity and inflation concerns. Risks include potential Fed rate hikes and narrowing market breadth. The high-yield sector faces pressure from bearish bets, but demand for yield provides support. Investors should weigh income stability against macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About iShares iBoxx $ High Yield Corporate Bond ETF
HYG is the world's largest high-yield bond ETF, tracking the Markit iBoxx USD Liquid High Yield Index. It provides liquid exposure to non-investment grade corporate debt, with 2026 top holdings including Cloud Software Group and Medline.
Read more on HYG →
